DRG 216 Overview

DRG 216 covers hospitalizations for cardiac valve and other major cardiothoracic procedures performed with cardiac catheterization when a Major Complication or Comorbidity is present. This group captures high-acuity surgical and interventional care involving valve repair or replacement, other major cardiothoracic operations, and concurrent diagnostic or therapeutic catheterization. It matters for Medicare payment because the presence of a Major Complication or Comorbidity substantially increases resource use and reimbursement relative to less complex cases. Accurate coding of procedures and coexisting conditions determines appropriate Medicare Severity Diagnosis-Related Group assignment and payment.

• Acute perioperative intervention trials assessing strategies to reduce intraoperative and immediate postoperative complications in patients undergoing cardiac valve surgery with concurrent cardiac catheterization. These studies typically enroll high-risk adults with severe valvular disease who require valve repair or replacement and concomitant diagnostic or interventional catheterization, and they test interventions such as optimized cardioplegia protocols, hemodynamic monitoring approaches, or fast-track anesthesia pathways. Findings are relevant to providers for refining surgical and anesthetic management to lower morbidity and to payers because reduced perioperative complications and shorter ICU stays can meaningfully affect cost and resource utilization for this high-cost DRG.
• Comparative effectiveness research comparing valve procedure approaches and timing in patients who undergo combined cardiothoracic surgery and catheterization, including comparisons of surgical techniques (e.g., repair versus replacement, biologic versus mechanical prostheses) or staged versus concomitant catheter-based diagnostics/interventions. These studies enroll heterogeneous populations (elderly patients, those with multivalvular disease, or with coronary artery disease discovered at catheterization) to determine which approaches yield better survival, fewer rehospitalizations, and lower complication rates. Results inform clinical decision-making and guideline development, helping providers choose strategies that balance clinical benefit with downstream costs and readmission risk that impact payer reimbursement under bundled payments.
• Post-discharge outcomes and care-transition studies focused on medium- to long-term recovery, anticoagulation management, and readmission prevention for patients after major cardiothoracic valve procedures with catheterization, often using registry-based cohorts or pragmatic trials of transitional care interventions. These studies examine patients discharged after complicated index admissions (including those with major complications coded as MCC), evaluating interventions such as structured follow-up, home-monitoring, or coordinated anticoagulation clinics to reduce thromboembolic events, bleeding, and early readmissions. Evidence from this research is important to providers to optimize outpatient care plans and to payers because improved post-discharge outcomes can reduce costly readmissions and improve value for episodes of care covered under DRG-based payment models.